VolitionRx develops blood-based diagnostic tests for cancer and sepsis with a focus on epigenetics. They are identifying novel biomarkers to detect cancer and sepsis early, enhance ease of disease monitoring, and ultimately save lives. This technology also attempts to accurately predict disease severity. VolitionRx employs advanced technologies to analyze circulating nucleosomes and other biomarkers in blood samples for diagnosis and prognosis, allowing physicians to act quickly and improve outcomes. By leveraging these scientific advancements, VolitionRx aims to provide accurate, non-invasive, and affordable diagnostic solutions that improve cancer detection and patient outcomes. Their innovative approach holds promise for transforming sepsis detection and cancer diagnosis in animals and humans.

VolitionRx

Founded: 2010
Location: Singapore, Singapore
Employee range: 11 - 50
Funding: $16.5M stock May 2023; $6M stock Jul 2022

Short description:

Drug notes:

Long description:

Jobs: